Design, development, and technical considerations for dry powder inhaler devices

被引:4
作者
Dhoble, Sagar [1 ]
Kapse, Archana [1 ]
Ghegade, Vaibhav [1 ]
Chogale, Manasi [1 ]
Ghodake, Vinod [1 ]
Patravale, Vandana [1 ]
Vora, Lalitkumar K. [2 ]
机构
[1] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Mumbai 400019, India
[2] Queens Univ Belfast, Sch Pharm, Belfast, North Ireland
关键词
COMPUTATIONAL FLUID-DYNAMICS; DRUG-DELIVERY; PERFORMANCE; DEPOSITION; ROUGHNESS; THERAPY; SULFATE; LACTOSE; SIZE;
D O I
10.1016/j.drudis.2024.103954
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The dry powder inhaler (DPI) stands out as a highly patient-friendly and effective pulmonary formulation, surpassing traditional and other pulmonary dosage forms in certain disease conditions. The development of DPI products, however, presents more complexities than that of other dosage forms, particularly in device design and the integration of the drug formulation. This review focuses on the capabilities of DPI devices in pulmonary drug delivery, with a special emphasis on device design and formulation development. It also discusses into the principles of deep lung particle deposition and device engineering, and provides a current overview of the market for DPI devices. Furthermore, the review highlights the use of computational fluid dynamics (CFD) in DPI product design and discusses the regulatory environment surrounding these devices.
引用
收藏
页数:12
相关论文
共 62 条
  • [1] Capsule-Based dry powder inhaler evaluation using CFD-DEM simulations and next generation impactor data
    Almeida, Lucilla C.
    Bharadwaj, Rahul
    Eliahu, Avi
    Wassgren, Carl R.
    Nagapudi, Karthik
    Muliadi, Ariel R.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 175
  • [2] Altounyan REC, 1970, US Patent, Patent No. 3518992
  • [3] Altounyan REC, 1970, US Patent, Patent No. 3635219
  • [4] Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases
    Anderson, Caleb F.
    Grimmett, Maria E.
    Domalewski, Christopher J.
    Cui, Honggang
    [J]. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2020, 12 (01)
  • [5] [Anonymous], Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children and Adolescents
  • [6] Computational fluid dynamic models as tools to predict aerosol distribution in tracheobronchial airways
    Atzeni, Claudia
    Lesma, Gianluca
    Dubini, Gabriele
    Masi, Maurizio
    Rossi, Filippo
    Bianchi, Elena
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Aulton ME., 2013, Aulton's pharmaceutics: the design and manufacture of medicines
  • [8] Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations
    Benque, Benedict
    Khinast, Johannes G.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 156
  • [9] Is there room for further innovation in inhaled therapy for airways disease?
    Biddiscombe, Martyn F.
    Usmani, Omar S.
    [J]. BREATHE, 2018, 14 (03) : 216 - 223
  • [10] Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes
    Borghardt, Jens Markus
    Kloft, Charlotte
    Sharma, Ashish
    [J]. CANADIAN RESPIRATORY JOURNAL, 2018, 2018